CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Current Assets:
Cash and cash equivalents	$ 12,416	$ 13,245
Available-for-sale securities	20,086
Prepaid expenses and other current assets	1,547	1,063
Total Current Assets	34,049	14,308
Property and equipment, net	30	6
Security deposits	20	14
Due from Callisto Pharmaceuticals, Inc.	3,306	1,542
Total Assets	37,405	15,870
Current Liabilities:
Accounts payable	5,255	1,416
Accrued expenses	2,060	1,331
Total Current Liabilities	7,315	2,747
Derivative financial instruments, at estimated fair value-warrants	5,258	3,325
Total Liabilities	12,573	6,072
Stockholders' Equity:
Preferred stock, Authorized 20,000,000 shares at December 31, 2012 and 2011, none outstanding.
Common stock, par value of $.0001. Authorized 100,000,000 shares at December 31, 2012 and 2011. Issued and outstanding 66,621,832 and 54,279,906 shares at December 31, 2012 and 2011, respectively	7	6
Additional paid-in capital	133,878	79,401
Deficit accumulated during development stage	(109,053)	(69,609)
Total Stockholders' Equity	24,832	9,798
Total Liabilities and Stockholders' Equity	$ 37,405	$ 15,870